PMID- 38150881
OWN - NLM
STAT- MEDLINE
DCOM- 20240118
LR  - 20240118
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 127
DP  - 2024 Jan 25
TI  - A systematic review of Janus kinase inhibitors and spleen tyrosine kinase 
      inhibitors for Hidradenitis suppurativa treatment.
PG  - 111435
LID - S1567-5769(23)01762-9 [pii]
LID - 10.1016/j.intimp.2023.111435 [doi]
AB  - BACKGROUNDS AND AIMS: Hidradenitis suppurativa (HS) is a challenging skin disease 
      with an underlying inflammatory process. Substantial progress has been made in 
      our understanding of HS over the last few years, with the advancement of novel 
      treatment approaches. The current systematic review aims to evaluate the safety 
      and efficacy of Janus kinase (JAK) inhibitors and spleen tyrosine kinase (Syk) 
      inhibitors in treating HS. METHOD: A thorough systematic search was performed on 
      PubMed/Medline, Web of Science, and Ovid Embase databases up to September 23th, 
      2023. Clinical studies published in English were included. RESULTS: Our search 
      yielded ten articles with a total of 165 patients treated with four types of JAK 
      inhibitors (upadacitinib, povorcitinib, tofacitinib, and baricitinib) and one Syk 
      inhibitor (fostamatinib). Upadacitinib, povorcitinib, and tofacitinib improved 
      clinical outcomes, with a significant reduction in hidradenitis suppurativa 
      clinical response (HiSCR) and abscess and inflammatory nodule count (AN count) 
      during the treatment period. Also, these drugs are well tolerated in most HS 
      patients with minimal adverse events (AEs). Moreover, baricitinib depicted an 
      amelioration in signs and symptoms of HS in one case report. Also, fostamatinib 
      exhibited favorable tolerability throughout a 12-week in moderate-to-severe HS 
      patients. The remarkable clinical improvement, as assessed through HiSCR and 
      hidradenitis suppurativa severity (IHS4), corresponded closely with serological 
      indicators of inflammation following fostamatinib administration was achieved. 
      CONCLUSION: JAK and Syk inhibitors are potentially efficacious in managing 
      moderate-to-severe HS since the proinflammatory cytokines are mediated by JAK and 
      Syk signaling pathways. However, further research with a more rigorous 
      examination is mandatory to evaluate such medication's long-term safety and 
      efficacy.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Heidari, Amirhossein
AU  - Heidari A
AD  - Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, 
      Iran. Electronic address: amirhosseinheidari.md@gmail.com.
FAU - Ghane, Yekta
AU  - Ghane Y
AD  - School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 
      Electronic address: yektaghanemd@gmail.com.
FAU - Heidari, Nazila
AU  - Heidari N
AD  - School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic 
      address: Nazila.heidari@yahoo.com.
FAU - Sadeghi, Sara
AU  - Sadeghi S
AD  - Department of Dermatology, Rasool Akram Medical Complex Clinical Research 
      Development Center (RCRDC), School of Medicine, Iran University of Medical 
      Sciences, Tehran, Iran; Department of Medicine, New York Health System, South 
      Brooklyn Hospital, Brooklyn, NY, USA. Electronic address: 
      sarasadeghimd@gmail.com.
FAU - Goodarzi, Azadeh
AU  - Goodarzi A
AD  - Department of Dermatology, Rasool Akram Medical Complex Clinical Research 
      Development Center (RCRDC), School of Medicine, Iran University of Medical 
      Sciences, Tehran, Iran. Electronic address: Azadeh_goodarzi1984@yahoo.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20231226
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - SQ8A3S5101 (fostamatinib)
RN  - ISP4442I3Y (baricitinib)
RN  - FYS6T7F842 (Adalimumab)
RN  - 0 (Janus Kinase Inhibitors)
RN  - 0 (Tyrosine Kinase Inhibitors)
RN  - EC 2.7.10.2 (Syk Kinase)
RN  - 0 (Aminopyridines)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 0 (Azetidines)
RN  - 0 (Purines)
RN  - 0 (Pyrimidines)
RN  - 0 (Morpholines)
SB  - IM
MH  - Humans
MH  - *Hidradenitis Suppurativa/drug therapy/diagnosis
MH  - Adalimumab/therapeutic use
MH  - *Janus Kinase Inhibitors/therapeutic use
MH  - Tyrosine Kinase Inhibitors
MH  - Spleen
MH  - Syk Kinase
MH  - Treatment Outcome
MH  - Severity of Illness Index
MH  - *Aminopyridines
MH  - *Pyrazoles
MH  - *Sulfonamides
MH  - *Azetidines
MH  - *Purines
MH  - *Pyrimidines
MH  - *Morpholines
OTO - NOTNLM
OT  - HS
OT  - Hidradenitis suppurativa
OT  - JAK inhibitor
OT  - Janus kinase inhibitor
OT  - Spleen tyrosine kinase inhibitor
OT  - Syk inhibitor
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/12/28 00:42
MHDA- 2024/01/18 06:43
CRDT- 2023/12/27 18:08
PHST- 2023/10/03 00:00 [received]
PHST- 2023/12/19 00:00 [revised]
PHST- 2023/12/20 00:00 [accepted]
PHST- 2024/01/18 06:43 [medline]
PHST- 2023/12/28 00:42 [pubmed]
PHST- 2023/12/27 18:08 [entrez]
AID - S1567-5769(23)01762-9 [pii]
AID - 10.1016/j.intimp.2023.111435 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2024 Jan 25;127:111435. doi: 10.1016/j.intimp.2023.111435. 
      Epub 2023 Dec 26.